[177Lu]pertuzumab: Experimental therapy of HER-2-expressing xenografts

Mikael Persson, Lars Gedda, Hans Lundqvist, Vladimir Tolmachev, Hans Nordgren, Per Uno Malmström, Jörgen Carlsson

Результат исследований: Материалы для журналаСтатьярецензирование

41 Цитирования (Scopus)

Аннотация

Pertuzumab (Omnitarg) is a novel antibody against HER-2, domain II. HER-2 is a tyrosine kinase receptor that is overexpressed in several carcinomas, especially breast cancer. Pertuzumab, labeled with the low-energy β emitter 177Lu, might be a candidate for targeted radiotherapy of disseminated HER-2-positive micrometastases. The radiolabeled antibody [ 177Lu]pertuzumab showed favorable targeting properties in BALB/c (nu/nu) mice with HER-2-overexpressing xenografts. The absorbed dose in tumors was more than five times higher than the absorbed dose in blood and more than seven times the absorbed dose in any other normal organ. Experimental therapy showed that [177Lu]pertuzumab delayed tumor progression compared with controls (no treatment, P < 0.0001; nonlabeled pertuzumab antibody, P < 0.0001; and 177Lu-labeled irrelevant antibody, P < 0.01). No adverse side effects of the treatment could be detected. Thus, the experimental results support the planning of clinical studies applying [177Lu] pertuzumab for therapy.

Язык оригиналаАнглийский
Страницы (с-по)326-331
Число страниц6
ЖурналCancer Research
Том67
Номер выпуска1
DOI
СостояниеОпубликовано - 1 янв 2007
Опубликовано для внешнего пользованияДа

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Подробные сведения о темах исследования «[<sup>177</sup>Lu]pertuzumab: Experimental therapy of HER-2-expressing xenografts». Вместе они формируют уникальный семантический отпечаток (fingerprint).

Цитировать